Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
15
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.
days to go:
Expired
investment:
£907,540
Feastr is a UK-based multi-brand cloud kitchen business that delivers restaurant-quality food to a customer's doorstep in 30 minutes or less. The company asserts that operating from cloud kitchens within densely populated areas allows it to exploit the booming food delivery market without the huge overheads associated with bricks and mortar restaurants. Feastr operates its restaurants on aggregators such as Deliveroo, Uber Eats, and Just Eat, capitalising on their huge ready customer base. The company has had sales of over £550,000 since its launch in November 2019. It will use the investment to open three new locations, push its digital marketing campaign with new ideas in 2021, and prepare for its next round of fundraising.
days to go:
Expired
investment:
£346,487
Staark makes cycling clothing that aims to cater to all body shapes. The company argues that current premium cycling and spin brands are cut to a single shape, optimised for the top 20% of cyclists. Staark intends to change this and bring its products to 80% of cyclists with high disposable income who are not ‘elite’ shaped. It delivers a fit based on specific body shapes using Dimensioning Technology (DT). Staark asserts that its innovative designs target cycling and indoor/spin for both men and women, with future diffusion into the wider Athleisure market, which is set to be worth $517 billion by 2025. The company has indicated that Spring 2021 is when it expects to launch its products. Staark will use the investment to enable the company to run its first productions, fueling the initial product launch.
days to go:
Expired
investment:
£161,035
Feed is a platform that automates digital advertising for musicians and creators by enabling them to grow an audience and build their businesses. The creator needs to connect their social media accounts to the Feed portal and set a budget. The portal will then create ads that reach new people and convert engaged audiences into loyal fans over time. The company asserts that existing ad generation platforms are too complex, time-consuming and expensive for creators. Feed argues that its portal caters to a variety of budgets, requires no marketing knowledge and takes minutes to get started. The beta platform is integrated with Facebook's & Instagram's ad network and has 500 creators on board. The company will use the investment to launch the paid version of Feed in Q4 2020.
days to go:
Expired
investment:
£146,117
